Group 1 - The core viewpoint of the article is the launch of the "Chenyue Capital" fund by Shanghai Kechuang Group, which aims to support the innovation and upgrading of the biopharmaceutical industry through three main models: large enterprise mergers and acquisitions, large enterprise outputs, and large enterprise incubation [1][2][3] - The fund will link various resources including government, industry, academia, research, finance, and application to drive industry innovation [1][2] - The "large enterprise sourcing" methodology proposed by the company focuses on creating a "core without borders" system to enhance the biopharmaceutical ecosystem [2][3] Group 2 - The first merger fund, "Chenyue New Dawn," has been established with a target total scale of 1.1 billion yuan and has completed its first acquisition transaction [3] - The company aims to assist government efforts in accelerating industrial aggregation to create a 100 billion yuan biopharmaceutical industry cluster in Shanghai [3] - The fund will also help large enterprises reduce costs and expand, while supporting startups in connecting with ecological resources to shorten their R&D and上市周期 [3]
上海提出“大企策源”新范式 加速生物医药产业链并购整合
Shang Hai Zheng Quan Bao·2025-07-04 19:00